Results 111 to 120 of about 664,970 (318)
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
Molecular Oncology, EarlyView.CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar +9 morewiley +1 more sourceInhalt, Vol. 12, Supplement 1, 1989 [PDF]
, 1989 Heinz Rüterjans, U. Büll, M. Steinbächer, G. Hör, Hartmut Döhner, F. Gückel, K.P. Schalk, J. P. Kaltwasser, Said l-Hadj, L. Staffenberger, E.S. Gussetis, U. Ebener, Stefanie Wehner, B. Kornhuber, R Bares, J. Faß, G. Weiller, Stefan Wolter, E. Kleinhans, S. Truong, V. Schumpèlick, T. Hölting, U Kretzschmar, P. Georgi, P. Schlag, R.P. Baum, M. Lorenz, A. Hertel, T. Baew-Christow, Andreas Schwarz, M. Pfreundschuh, Patrice Carde, L. Da Costa, L. Manil, J Lumbroso, B. Caillou, F. Boudet, M. Ricard, M Hayat, V. Diehl, J.-C. Saccavini, F. Gückel, W. Knauf, Anthony D. Ho, W. Semmler, G. van Kaick, J. Ruhlmann, A. Bockisch, W. Dewes, U. Loos, A. Hotze, H.-J. Biersack, Judith Jeske, Karl Herholz, W Heindel, W.-D. Heiß, W. Semmler, P. Bachert-Baumann, G. Gademann, H.-J. Zabel, G. van Kaick, Rüdiger E. Port, L.G. Strauss, John H. Clorius, C. Parmentier +64 moreopenalex +1 more sourceImproving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann +15 morewiley +1 more sourceSupplemental Figures and Tables from Notch4 Signaling Induces a Mesenchymal–Epithelial–like Transition in Melanoma Cells to Suppress Malignant Behaviors
, 2023 Ehsan Bonyadi Rad, Heinz Hammerlindl, Christian Wels, Ulrich Popper, Dinoop Ravindran Menon, Heimo Breiteneder, Melitta Kitzwoegerer, Christine Häfner, Meenhard Herlyn, Helmut Bergler, Helmut Schaider +10 moreopenalex +1 more sourceCytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway
Molecular Oncology, EarlyView.Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock +10 morewiley +1 more sourceSupplemental Table 1 from Eradication of Acute Myeloid Leukemia with FLT3 Ligand–Targeted miR-150 Nanoparticles
, 2023 Xi Jiang, Jason Bugno, Chao Hu, Yang Yang, Tobias Herold, Jun Qi, Pïng Chen, Sandeep Gurbuxani, Stephen Arnovitz, Jennifer Strong, Kyle Ferchen, Bryan C. Ulrich, Hengyou Weng, Yungui Wang, Hao Huang, Shenglai Li, Mary Beth Neilly, Richard A. Larson, Michelle M. Le Beau, Stefan K. Bohlander, Jie Jin, Zejuan Li, James E. Bradner, Seungpyo Hong, Jianjun Chen +24 moreopenalex +1 more source
